Pathology of nonalcoholic fatty liver disease
- PMID: 17951208
- DOI: 10.1309/RTPM1PY6YGBL2G2R
Pathology of nonalcoholic fatty liver disease
Abstract
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are gaining increasing recognition as components of the emerging epidemic of obesity in North America and in other parts of the world. These entities are considered the hepatic manifestations of the insulin resistance syndrome and represent the spectra of fatty liver disease associated with it. All features of metabolic syndrome are associated with NAFLD/NASH, including obesity, type 2 diabetes, arterial hypertension, and hyperlipidemia in the form of elevated triglyceride levels. NAFLD/NASH can progress to liver cirrhosis and has been reported as a cause of hepatocellular carcinoma. In this review, the histopathologic features of NAFLD/NASH and differential diagnostic considerations are discussed. In addition, grading and staging schema proposed and currently in use are reviewed. Finally, other aspects for consideration by practicing pathologists, such as sampling issues, histopathologic findings after therapeutic interventions, and recurrence after liver transplantation, are addressed.
Similar articles
-
Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems.Eur J Gastroenterol Hepatol. 2010 Jun;22(6):643-50. doi: 10.1097/MEG.0b013e32832ca0cb. Eur J Gastroenterol Hepatol. 2010. PMID: 19478676 Review.
-
Nonalcoholic steatohepatitis.Semin Liver Dis. 2004 Feb;24(1):3-20. doi: 10.1055/s-2004-823098. Semin Liver Dis. 2004. PMID: 15085483 Review.
-
Nonalcoholic fatty liver disease: defining a common problem.Eur Rev Med Pharmacol Sci. 2005 Sep-Oct;9(5):253-9. Eur Rev Med Pharmacol Sci. 2005. PMID: 16231586 Review.
-
[Nonalcoholic steatohepatitis--a "new" hepatic disease].Ugeskr Laeger. 2003 Mar 10;165(11):1115-8. Ugeskr Laeger. 2003. PMID: 12677985 Review. Danish.
-
Nonalcoholic fatty liver disease in severely obese subjects.Am J Gastroenterol. 2007 Feb;102(2):399-408. doi: 10.1111/j.1572-0241.2006.01041.x. Am J Gastroenterol. 2007. PMID: 17311652
Cited by
-
Polydatin: A Critical Promising Natural Agent for Liver Protection via Antioxidative Stress.Oxid Med Cell Longev. 2022 Feb 10;2022:9218738. doi: 10.1155/2022/9218738. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 35186191 Free PMC article. Review.
-
MR imaging of liver fibrosis: current state of the art.Radiographics. 2009 Oct;29(6):1615-35. doi: 10.1148/rg.296095512. Radiographics. 2009. PMID: 19959511 Free PMC article. Review.
-
Hypertension and hepatic steatosis.Curr Hypertens Rep. 2008 Jun;10(3):182-7. doi: 10.1007/s11906-008-0035-9. Curr Hypertens Rep. 2008. PMID: 18765087 Review.
-
Hepatic Innervations and Nonalcoholic Fatty Liver Disease.Semin Liver Dis. 2023 May;43(2):149-162. doi: 10.1055/s-0043-57237. Epub 2023 May 8. Semin Liver Dis. 2023. PMID: 37156523 Free PMC article. Review.
-
Role of liver biopsy in nonalcoholic fatty liver disease.World J Gastroenterol. 2014 Jul 21;20(27):9026-37. doi: 10.3748/wjg.v20.i27.9026. World J Gastroenterol. 2014. PMID: 25083076 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources